Embecta Aktie News

Despite an 8.2% forward yield, be careful with Perrigo, due to its value trap reputation. Yielding 6.7%, Pfizer is a strong choice among high-yield dividend stocks, given the company's post-COVID-19 catalysts.

Embecta Corp. (EMBC) Q1 2026 Earnings Call Transcript

PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results.

PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock.

PARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal first quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Easter...

Embecta Corp. (EMBC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

PARSIPPANY, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P.

Embecta Corp. (EMBC) faces a challenging fiscal 2026, with flat revenue and earnings growth expected - after a strong fiscal 2025. EMBC's weak outlook is driven by cannula costs, modest volume declines, and higher R&D expenses, despite improved margins and debt reduction. The dividend yield of 4.77% may appeal to income investors, but near-term growth prospects remain limited, warranting a Hold...